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Congressman 
Barney Frank to Speak 
in Portland I PRO.JECT 
Art Auction Raises 
Funds for TAP by Demetra Giatas 
TAP Development Director 
Massachusetts Congressman Barney Frank, an openly 
gay member of the U.S. House of Representatives, is coming to 
Portland on Saturday, April 24th to speak at the launching of an 
annual event called "The Frannie Peabody Lecture Series", 
which is a collaborative fundraising event to benefit The AIDS 
Project, Peabody House, and the AIDS Lodging House. 
The lecture will be held at First Parish Church at 425 
Congress Street in Portland. The lecture begins at 7 :30 p.m. and a 
champagne and dessert reception follows at 8:45 p.m. For more 
information or to buy tickets, please call TAP at 77 4-6877 
And, thanks to the wonderful support of the community, 
artists, committee members, volunteers and, of course, the 
attendees and art purchases at the Spring for Life Art Auction in 
March. The Auction raised gross receipts of $90,000 -- a record 
amount! 
Many thanks to everyone for their hard work and support! 
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BYTHEWAY by Mike Martin 
Let me start with an apology. I'm sorry that the numbers, they reported either great results or disappoint-
size of the type in much of this issue is kind of small. ment. These conversations simply reinforce my percep-
Each month I put together a file folder that holds all the tion that the new drugs are not the total panacea we want 
information I think will be of interest to our readers. them to be. A couple of the news items in this newsletter 
Some months it seems a little thin; other months, like this comment on research into the side effects of these new 
one, it is overflowing with good stuff. So, I have to drugs, research that has followed people who have been 
decide. Bigger print and fewer stories or smaller print taking the drugs for some time now. For the first time, I 
and more stories? My bias is always to go with more have detected a real note of caution in the medical 
news and information. So grab onto your magnifying community about when to begin treatment and whether 
glasses and read away. or not some of the side effects have greater immediate 
Several weeks ago, The AIDS Project held its harmful consequences than the virus itself. 
annual Spring for Life Art Auction. As always, it was a The other thing I heard in my conversations, and 
phenomenal event. When I think of the talent behind the which I feel myself, is that the decision on what drugs to 
many pieces of art, the time and energy it takes to plan take is not an easy one. With more and more drugs now 
the event, and the logistics of moving the art, I am available, each with its own set of side effects to con-
overwhelmed. But, as before, everything came off sider, it is now harder to decide, or to even know, what 
without a hitch and a tidy sum of money was raised to combination is best to take. And I also heard from some 
benefit TAP and its clients. Let me echo Demetra friends that when the drugs stop working, viral loads 
Giatas's comments (on page one) to say, "Well done, seemtoreallyincreaserapidly(andthat'snotgood). 
everyone!Andthankyousoverymuch." On the plus side, we have more options, more 
In the past month I've talked to a few people choices. The trick now is to learn what seems to work 
living with HIV about their management of their disease best. It is a process that people with HIV are learning "as 
with the combination drug therapies. In almost equal they go" in the life of their disease. 
~ 
~,~------------------------
Immediate Seating Update 
from Daniel Schnorbus, TAP's Client Services Coordinator 
There will now be another way to access tickets from the "Immediate Seating" program at The AIDS 
Project. Simply cut out and fill in this coupon and TAP will call you if tickets that match your interests 
become available. So, please fill out the coupon completely and then mail it or drop it off at" 
/i:m 
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The AIDS Project 
Attention: Daniel Schnorbus 
625 Congress Street (if in person) 
P.O. Box 5305 (if by mail) 
Portland, Maine 04101 
Your Name ______________ Daytime Phone ____ _ 
Address ______ City _____ State __ Zip Code ___ _ 
May we leave a message at your phone number? Yes __ No __ 
Areas of Interest: 
Musical Events _Sports Events Movies 
Theater Events TAP Functions Other 
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HIV Drug News 
A Contraceptive Returns to the Market 
New York Times (03/30/99) 
The contraceptive sponge will return to the U.S. market 
after being pulled in 1995. The device, once the most 
popular non-prescription birth control devices for women, 
will be manufactured and marketed by Allendale 
Pharmaceuticals, which bought the rights to the product 
from American Home Products. Contraceptive sponges 
have not been shown to protect against sexually 
transmitted diseases, although the spermicide used in the 
product may confer some protection against them. 
Glaxo Gets FDA Approval to Add Claims for AIDS-Drug 
Wall Street Journal (03/25/99) 
The FDA has approved measures allowing the U.S. unit of 
Glaxo Wellcome to extend marketing claims for its anti-HIV 
drug Epivir, also known as 3TC. Glaxo Wellcome announced 
that the FDA will allow the marketing of the drug in a liquid 
form for infants and children, and in an oral form for 
adolescents. Glaxo Wellcome will also be allowed to market 
3TC for use in combination with other anti-HIV medications. 
The drug is one of the more commonly prescribed anti-HIV 
medications already often used in combination therapy. 
HCFA Mandates Medicaid Reimbursement 
of Drug for AIDS Wasting 
Reuters Health Information Services (04/06/99) 
A press release from the National Association for People 
With AIDS states that the Health Care Financing 
Administration is requiring all states to provide Medicaid 
reimbursement for the recombinant human growth 
hormone Serostim, a treatment for AIDS wasting. The 
decision reverses a previous HCFA ruling that allowed 
states to refuse Medicaid coverage for the drug, classifying 
it as a treatment for cosmetic weight gain. 
Vaginal Creams Can Cause Condom Failure 
Reuters Health Information Services (03/30/99) 
Certain vaginal creams can cause condom failure, report 
researchers from Baylor College of Medicine in Houston. 
The scientists exposed 20 condoms to 10 over-the-counter 
vaginal creams for five minutes each, observing that 
condoms exposed to products with vegetable or mineral 
oils took less time to burst when inflated with air. The 
researchers, who report their findings in the Southern 
Medical Journal, note that vaginal products containing 
vegetable or mineral oils may be associated with decreased 
condom integrity. They advised women using over-the-
counter vaginal products containing the substances to use 
caution. 
Abbott Asks FDA to Approve New Form of AIDS Drug 
Reuters (03/31/99) 
Abbott Laboratories Wednesday submitted an 
application to the FDA seeking permission to produce a new 
capsule form of its AIDS drug Norvir, which has been in 
limited supply because of problems related to production. 
Abbott indicated it began work on the soft-gel capsule form 
after production problems last September forced some 
consumers using the drug to switch to a liquid form. 
Although the drug maker said it could not determine when it 
would get regulatory approval, it said patients would still 
have access to the liquid form. 
HIV Drug News 
HIV Drug Treatment Successes and Failures 
Lancet (03/13/99) 
The Swiss HIV Cohort conducted a study of 2,674 HIV-
infected patients receiving highly active antiretroviral 
therapy (HAART) and found that the subjects had a high 
rate of virological failure, but a low rate of clinical 
progression to AIDS. Of those treated, over 90% achieved 
undetectable viral loads by one year; pre-treated patients 
had lower rates of undetectable viral levels. Viral rebound 
was seen in about one-fifth of treatment-naive patients 
after two years at undetectable viral levels, and up to 40% 
of pre-treated patients. After 30 months, about 6.6% of 
patients who had undetectable viral levels, 9% of those 
who showed viral rebound, and 20.1 % of patients who 
never reached undetectable viral levels progressed to 
AIDS or died. 
The authors note that a second regimen was often 
required in patients on HAART due to the high rate of 
virological failure. They recommend that ''virological and 
immunological responses should be assessed before 
HAART is taken to be failing and the regimen is modified, 
especially because the number of available treatment 
options is limited." They further suggest controlled trials 
to determine the optimum initiation point for HAART. 
Cost as a Barrier to Condom Use: 
American Journal of Public Health (04/99) 
The cost of condoms can act as a barrier to use, 
according to a study by Louisiana researchers. The study 
recruited 195 of over 1,000 businesses distributing free 
condoms, replacing the free condoms with low-cost 
condoms (25 cents). Pre-and post-test surveys measured 
condom use among participants reporting two or more 
sexual partners. The percentage of respondents who 
obtained condoms through the businesses dropped from 
57% to 30% after the 25-cent charge was introduced. The 
percentage of people reporting condom use during their 
last sexual encounter fell from 77% to 64% after the 
introduction of the charge. The authors conclude that ''free 
condoms should be distributed to encourage their use by 
persons at risk for HIV and other sexually transmitted 
diseases." 
Program Increases HAART Adherence in HIV Patients 
AIDS Alert (03/99) 
A pilot program at a Rhode Island hospital appears to 
increase highly active antiretroviral therapy adherence 
rates. Thus iar, only one month of the six-month project, 
which involves patients who were referred by physicians 
because of compliance problems, has been studied; 
however, the results show potential. At baseline, 75% of 
the patients said they had missed a dose of their regimen 
within the previous four days; but after one month of the 
program, only 22% said they had missed a dose. 
Enrolled patients have their medications brought to 
them weekdays by peer outreach workers, who watch 
them take the morning dose and also check to see if the 
previous day's treatments had been taken. The workers 
also leave daily pill packets for the weekends. In all, the 
program cost less than $40,000 for the first six months 
and has grown to 23 patients from the original nine. As 
patients progress in the program, medications are taken to 
them on a less frequent basis. However, if the patient 
appears to be having problems, the number of visits will be 
increased. 
HIV Vaccine News 
U.N. AIDS Chief Says No Vaccine for At Least 10 Years 
Fox News Online (03/17/99) 
The head of the Joint U.N. Program on HIV/AIDS, Dr. 
Peter Piot, said Wednesday that an HIV vaccine will not be 
available for at least 1 O more years. Piot added that 
prevention is the only current option available for reducing 
the spread of the virus, which infects 35 million people 
worldwide. Piot also noted that the disease is increasingly 
affecting young people and that ''there's still far too little 
attention given to AIDS." 
UNAIDS is trying to increase this year's HIV-prevention 
efforts in Africa; Zimbabwe, Swaziland, Botswana, 
Namibia, and South Africa are estimated to have 25 percent 
to 33 percent of their adult populations infected with the 
virus. HIV is also expected to cause a significant decline in 
the life expectancy of these populations, resulting in 
economic problems. 
Trials of Local HIV Vaccine to Begin 
Age Online (03/29/99) 
The Australian National Council on AIDS and Related 
Diseases recently determined that a number of possible 
Australian-produced vaccines against HIV are ready for 
future development and could enter phase I trials within the 
next few months. 
Trials involving human subjects could begin as soon as 
next year. Even though the trials are likely to be given fast-
track status, the chairman of the council's clinical trials and 
treatment advisory committee said that a vaccine against 
the virus would probably not be available for seven to 10 
years. Preventive and therapeutic vaccines will both be 
considered, and trials will be undertaken in both developed 
and developing nations. 
First Trial of HIV Vaccine Begins in Thailand 
Reuters (03/24/99) 
HIV vaccine trials will begin today in Thailand, with six 
volunteers receiving their initial inoculations. The subjects 
all use injection drugs and are the first of 2,500 people in the 
country to be involved in the three-year clinical trial. Half of 
the subjects will receive the vaccine, while the other half 
will be given placebo. The vaccine was developed by 
VaxGen in the United States and is designed to confer 
resistance against the HIV strain prevalent in Thailand, the 
rest of Asia, and the Pacific Rim. 
Drug Makers Still Reluctant to Invest in HIV Vaccine 
Albany Times Union Online (03/14/99) 
The Pharmaceutical Research and Manufacturers of 
America reports that pharmaceutical companies are 
currently investigating 101 new drugs for HIV-infected 
individuals. However, the firms are supporting only 12 
experimental vaccine proposals, and only VaxGen's AIDS 
vaccine has received Food and Drug Administration 
approval for large-scale human testing. 
According to Dr. Peggy Johnston, the assistant director 
for AIDS vaccines at the National Institute for Allergy and 
Infectious Diseases, drug firm executives are concerned 
that too little is known about how HIV functions to justify 
significant investment. 
Other problems include the various strains of HIV and the 
fact that the average vaccine costs $100 million to develop, 
although the totals for an HIV vaccine could be much higher 
and the completion date much further off . 
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HIV and Youth 
Treatment Issues for HIV-Positive Adolescents 
AIDS Clinical Care (03/99) 
HIV infection in adolescents may have different features 
compared to infection in adults. The Reaching for 
Excellence in Adolescent Care and Health (REACH) study is 
currently investigating infection differences found in 
younger patients. Initial findings indicate that adolescents 
may have a greater potential for immune reconstitution due 
to the presence of residual thymic tissue. Other studies 
show that most youth acquired their infection through 
sexual transmission during adolescence and begin care 
when asymptomatic, with moderate immune dysfunction. 
Perinatally infected children who survive to adolescence 
often have advanced disease. 
According to the Montefiore Adolescent AIDS Program, 
there are four primary issues that HIV-infected youth need 
to address in coping with their health status: receiving an 
HIV diagnosis, disclosing status to family and others, 
coping with illness, and preparing for death. Infected 
adolescents may have problems with mental illness and 
substance abuse, both of which are important co-
morbidities for HIV-positive youth. These problems should 
be identified and addressed in patients to help them 
successfully cope with their disease and for the 
maintenance of antiretroviral adherence. Providers should 
be aware of the local legal issues in regard to the treatment 
of adolescents with sexually transmitted diseases. For 
routine health care, HIV-positive adolescents should be 
routinely screened for other STDs, while tuberculosis 
screening should be performed according to guidelines in 
place for HIV-infected adults. 
Pharmokinetics may differ in adolescents, and 
antiretrovirals may have interactions with commonly 
prescribed medications in younger patients. The AIDS 
Clinical Trials Group is currently undertaking measures to 
institute adolescent-relevant trials to improve treatment 
measures for infected youth. 
HIV and Youth 
Low Cardioraspiratory Fitness in HIV+ leans 
Reuters Health Information Services (03/29/99) 
Researchers at the University of Maryland in Baltimore 
report that many HIV-infected teenagers have poor 
cardiorespiratory capacity. The researchers concluded 
that HIV-infected adolescents may have diminished 
physiological capabilities that may limit them to light 
physical activity. The study focused on nine HIV-positive 
teens who received combination therapy. The subjects 
reported low energy levels but were unaware thatthe their 
fatigue was caused by their HIV status. 
Beyond AIDS: Taanagers and sm•s 
Washington Post (03/23/99) 
Many teenagers in the U.S. are informed about the 
dangers of HIV, but they are often unaware of many other 
common sexually transmitted diseases. A recent national 
survey of 15-17 year olds found that they seriously 
underestimated their risk of contracting STD's other than 
HIV. About one-third of the respondents who were 
sexually active felt they were at risk for acquiring an STD, 
and few had been tested for infection. Less than half knew 
that herpes and human papillomavirus have no known 
cure or that gonorrhea and syphilis can be cured. 
Teens are at a higher risk for contracting STD's 
compared to many other groups, with three-fourths of 
non-HIV STD's occurring in people aged 15 to 24. Many 
infected people are asymptomatic and unaware that they 
have an STD. STD's can later result in cancer, infertility, 
neurological diseases, and death. 
The CDC's Dr. Helene Gayle explains that ''we as a 
society have not talked openly about STD's. There are 
severe consequences, particularly for young women." In 
addition to health issues, Gayle notes that STD's other 
than HIV cost about $8 billion a year to diagnose and treat. 
HIV and Youth 
Students Believe Pill Can Stop AIDS 
UK Independent Online (03/13/99) 
New research into the sexual knowledge of British youth 
indicates large gaps. The "Young People and Health" survey, 
which involved more than 10,000 11- to 16-year-olds, 
revealed that only 39 had heard of gonorrhea, one-third of 
syphilis, and 51 percent of herpes. More than 25 percent 
believe the contraceptive pill will guard against STDs. The 
study also found that the teens want more information 
about AIDS. 
'The Talk' With Kids Should Occur Early, Often 
Washington Post (04/06/99) 
A new survey funded by the Kaiser Family Foundation 
and Children Now indicates that talking about sex with their 
children is still hard for parents. Kaiser's Tina Hoff notes that 
the issue is difficult, "but once you break this barrier, you 
have really crossed a communication line." 
The study found that nearly 50 percent of parents of 1 O-
to 12-year-olds have not broached the topic of how to deal 
with peer pressure to have sex, and 60 percent of parents 
have not discussed pregnancy and sexually transmitted 
disease prevention. However, according to the survey, pre-
teens are likely to be open to the information; almost 40 
percent of 10- to 12-year-olds report that their peers get "a 
lot" of AIDS, sex, drugs, and alcohol information from their 
mothers. An equal percentage reported obtaining 
information from television/movies and schools/teachers. 
Over 60 percent of 13- to 15-year-olds reported friends and 
television/movies as the primary information sources, 
followed by schools and teachers, the Internet, and 
mothers, respectively. New York parenting expert Lynne S. 
Dumas notes that sex education should be an on-going 
discussion, not just a one-time conversation. 
Need a home for unused medications? The folks at AID for AIDS has an idea. They are often asked if they can 
forward unused medications to clients who need them. For legal reasons, they must so "no". But, before you 
throw those medications away, consider mailing them! AID for AIDS is a non-profit organization that 
distributes HIV medications and information to Latin America. They provide a life-saving service to people 
who would not ordinarily have access to HIV meds. Currently, AID for AIDS has a waiting list of over 30 
people who need all types of medications. You can send meds you no long use to: 
AID for AIDS 
P.O. Box 1862, Old Chelsea Station 
New York, NY 10113 
Or call AID for AIDS at 212-358-9715 
The AIDS Project 
615 Congress Street - 6th Floor 
(or 142 High Street) 
P.O. Box5305 
Portland, Maine 04101 
Phone: 774-6877 Fax: 879-0761 
E-mail: tap@aidsproject.org 
Website: www.aidsproject.org 
AIDS Hotline: 775-1267 
or 1-800-851-2437 
York County Office 
Lafayette Center - 4th Floor 
Kennebunk, ME 04043 
Phone: 985-8199 
Fax: 985-8646 *51 
E-mail : tap2@mail.javanet.com 
Staff: 
Doug Bailey, 
HAVEN I Housing Coordinator 
Declan Buckley, 
MSM Outreach Worker 
Diana Carrigan, 
Cumberland County Case Manager 
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Janine Collins, 
Cumberland County Case Manager 
John Cronin, 
MSM Outreach Worker 
Carolyn Curtis, 
Case Management Intern 
Sequoia Dance, 
Street Outreach Worker 
Douglas Eaton, 
Program Coard. of HIV Prevention 
Denise Ferer, 
York County Case Mngmt. Intern 
Jill Frame, 
HAVEN Case Manager 
George W. Friou, 
Executive Director 
Demetra Giatas, 
Development Director 
John Green, 
HIV Case Manager 
John Holverson, 
Director of Prevention and Education 
Gloria Leach, 
Community HIV Prevention Educator 
Nicole Lebrecque, 
Intern 
Annette Lemek, 
Case Management Intern 
Randy May, 
Director of Support Services 
Rebecca Neel, 
Cumberland and York Counties 
Case Manager 
Susan Parr, 
Cumberland County Case Manager 
Getty Payson, 
York County Case Manager 
Steve Reevy, 
Manager I Finance & Administration 
Daniel Schnorbus, 
Client Services Coordinator 
Gerry Scoppettuolo, 
York County Field Outreach Worker 
David Aaron Swander, 
Education I Development Assistant 
Kerry S. Tardiff, 
Administrative I Case Management Assistant 
Art Waller, 
Accounting Assistant 
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HIV and Youth 
Cash Changes Sex Ed Doctrine 
Washington Post (04/05/99) 
Almost 700 abstinence-only programs were established 
last year by states using federal funding, according to the 
Sexuality lnfonnation and Education Council of the United 
States (SIECUS). A provision in the 1996 federal welfare 
refonn bill will provide nearly $500 million of state and 
federal funds for abstinence programs over five years. 
SIECUS president Debra W. Haffner notes that the "influx of 
money has influenced what infonnation young people are 
receiving about sexuality," although the group adds that, in 
general, most of the new programs did not replace other 
"comprehensive" sex education measures. 
In Georgia, Mississippi, Oklahoma, Indiana, and North 
Carolina, there are now laws requiring abstinence-only-
until-marriage as the standard for students. According to 
the SIECUS report, only two states -- California and New 
Hampshire -- have not received funding through the 
program, and 22 states have adopted abstinence-only 
programs in schools. 
Cabin Fever Getting You Down? 
Go Take a Hike! 
The AIDS Project and the University of New 
England are teaming up to bring clients a 
wonderful opportunity. Come enjoy the fresh air 
and meet other people for student-led, easy/non-
strenuous walks and hikes around Cumberland 
and York counties. 
These free Outdoor-Wellness groups will be 
happening once a month and will provide you 
with a way to be outside in a safe and social 
atmosphere, while getting some exercise and 
enjoying the beautiful seacoast of Maine. 
All those interested may call Denise at 
985-8199 to sign up or to get more information. 
Don't miss out on this great chance to meet 
others, have fun, and see the beautiful sites of 
southern Maine. 
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HIV and Needles 
Needle Exchanges Don't Spur HIV, Study Suggests 
Calgary Herald Online (03/29/99) 
A survey of 700 injection drug users in Vancouver 
indicates that people who use needle-exchange programs 
are not likely to increase high-risk behaviors for HIV. Dr. 
Martin Schecter, lead author of the study, said that the 
study would be helpful in generating support for the 
programs. Schecter, of the University of British Columbia, 
noted that opponents to needle-exchanges had been 
using one of his previous studies to support their cause, 
asserting that "people were quoting our study in [the U.S.] 
Congress, using it to suggest that the needle exchange in 
Vancouver made things worse." He added that he felt the 
study - which concluded that the HIV rate was nearly 
double among frequent users of exchanges compared to 
infrequent users -- was being misinterpreted, and he 
hopes that the present data will clear any confusion. While 
needle exchanges help raise HIV awareness in 
communities, said Schecter, other programs are needed 
to properly combat the spread of the virus. 
Needle Program Doesn't Increase Crime 
Baltimore Sun (03/30/99) 
Researchers from the Johns Hopkins School of Public 
Health have found that a Baltimore needle-exchange 
program has not contributed to drug-related crime or to 
the number of discarded needles in the street. According 
to the scientists, arrest patterns in areas with a needle-
exchange program did not differ significantly from 
patterns in other parts of the city. Baltimore's health 
commissioner, Dr. Peter Beilenson, said the study should 
help address concerns that needle exchanges contribute 
to the drug problem by sending a message that condones 
drug use. Currently, Baltimore spends over $570,000 on 
programs for intravenous drug use, including treatment 
and needle exchanges. Beilenson said that the addition of 
federal funding would allow the city's program, one of the 
largest in the nation, to expand; however, a bill in the U.S. 
Senate would pennanently ban the use of federal funds for 
needle-exchange programs. 
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HIV and Needles 
Health Care Worker's Occupational Exposures 
To Needle Sticks 
Journal of the American Medical Association (03/99) 
Researchers from Rush Medical College in Chicago and 
the University of Colorado Health Sciences Center at Denver 
analyzed HIV-1 genomes isolated from patients at a health 
care clinic to detennine the prevalence of antiretroviral 
resistance. The scientists sought to determine health care 
workers' (HCW) risk of exposure to drug-resistant HIV 
strains, perfonning genotypic analysis on 15 isolates taken 
from individuals who were involved as source patients in 
HCW occupational exposure. None of the patients had 
received protease inhibitors, while 1 O had taken zidovudine, 
five didanosine, three lamivudine, two zalcitibine, two 
stavudine, and one nevirapine. The researchers found a 
high prevalence of antiretroviral resistance, with mutations 
associated with reverse transcriptase therapy seen only in 
patients who received antiretroviral therapy. 
The authors note that the transmission of resistant HIV 
strains has been reported, adding that "given the increasing 
utilization of combination antiretroviral therapy, and the 
growing number of patients harboring drug-resistant virus, 
the potential exists for HCWs to become infected with 
multidrug-resistant HIV through occupational exposure." 
They suggest that patient treatment history may be helpful 
in determining postexposure prophylaxis regimens for 
exposed HCW's. 
'Safe Needles' Urged to Protect Health Staff 
Chicago Sun-Times Online (04/05/99) 
Statistics from the Centers for Disease Control and 
Prevention reveal that 1,800 needlestick accidents 
occurred at six hospitals over a two-and-one-half-year 
period. According to the CDC, there have been 45 confinned 
HIV infections and 1,000 hepatitis B infections as a result of 
needlesticks. 
The risk of a health care worker contracting HIV from a 
needle from an infected individual is one in 200. However, a 
variety of new products aim to reduce that risk, including a 
needle that automatically retracts after use. 
In Illinois, the state House has approved a law requiring 
public hospitals and clinics to use safe needles. The 
measure, now pending in the state Senate, is opposed by 
the Illinois Hospital and Health Systems Association, which 
claims the government should allow the hospitals and 
clinics to come up with their own solutions. 
Addicts Wary of New Program 
Portland Press Herald Online (03/14/99) 
Maine's first needle-exchange program was launched in 
January in an effort to keep the estimated 500 to 700 
injection drug users in Greater Portland from contracting 
and spreading HIV. While the Portland program received 
widespread support in the community, organizers note that 
the addicts themselves have been slow to accept the 
exchange and only about a dozen IDU's are currently 
enrolled. Organizers of the city's needle exchange program 
say they anticipated the slow beginning and believe that 
more IDU's will come to prevent infection. 
The Portland needle exchange is funded by private 
groups, certified by the state, and governed by strict federal 
standards on biohazardous waste. 
-~~ 
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HIV Medical Science 
Common Protein May Link Viruses 
United Press International (03/25/99) 
Research conducted at Northwestern University 
indicates that there are similarities between the Ebola virus, 
HIV, and the pathogens that cause measles, mumps, and 
other infections. Scientists determined the structure of a 
protein that the viruses use to enter host cells. The protein, 
called the "fusion protein," snags the membrane of a host 
cell, allowing the virus to enter the cell. The discovery, 
which is documented in the March edition of Molecular 
Cell, may help scientists develop antiviral medications. 
Hit the Dirt 
POZ(03/99) 
New research indicates that the mineral selenium, 
which is nontoxic at appropriate doses, could slow the 
progression of HIV, possibly preventing viral replication. 
University of Miami researchers found that selenium-
deficient HIV-infected subjects had a significantly increased 
risk of death. The relative risk of death for deficient patients 
was 20 times the risk for non-deficient patients, even after 
adjusting for CD4 cell counts. 
The researchers also found higher rates of death 
associated with vitamin A, vitamin B-12, and zinc 
deficiencies. The researchers are conducting a 328-person 
trial to assess the effects of selenium administration on 
disease progression. 
Scientists Figure Out How 
Immune System Remembers 
Boston Globe (03/13/99) 
Researchers from the University of Chicago have 
discovered how the immune system "remembers" previous 
attackers, a finding that could eventually lead to improved 
vaccines and possibly treatment for HIV. 
According to the scientists, who reported their findings 
in the journal Science, the process by which memory cells 
are produced is extremely slow. Following an attack by 
viruses or cells that are starting to become cancerous, T-
cells move quickly to the site and multiply; however, after a 
time, the majority of the extra T-cells die off -and the few 
cells that remain have a memory imprint of the attacker. 
Yet, researcher Philip Ashton-Rickardt notes, that at least 
five cycles of cell division are necessary for any of these 
cells to develop, and it could be for this reason that no AIDS 
vaccine to date has succeeded. 
2 Human Proteins Isolated That Kill HIV, Report Says 
Baltimore Sun (03/16/99) 
Scientists have discovered that the urine of pregnant 
women, as well as human tears and saliva, contains 
proteins that have potent anti-HIV effects. The findings, 
reported in the Proceedings of the National Academy of 
Sciences, show that the protein lysozyme, a natural 
compound that the body routinely produces and which is 
found in human saliva and tears, killed HIV rapidly in test-
tube studies. 
Another kind of protein, ribonucleases, which are found 
in pregnant women's urine, was found to attack the genetic 
material of HIV. New York University researcher Sylvia Lee-
Huang, a member of the team that identified the proteins' 
abilities, speculated that drugs made from them could be 
better tolerated and have fewer side effects than existing 
HIV therapies. 
~ 
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HIV Drug News 
AIDS Researchers Target Poor Adherence 
Journal of the American Medical Association (03/99) 
Researchers at the Sixth Conference on Retroviruses 
and Opportunistic Infections in Chicago presented 
findings on HIV-infected patient adherence to medical 
regimens. Using an electronic device called MEMScaps -
bottle caps containing microelectronics that measure and 
record when the bottle has been opened ·· scientists from 
the VA Medical Center in Pittsburgh and elsewhere found 
that even patients who skipped only a few doses of highly 
active antiretroviral therapy (HAARTI showed virologic 
failure. According to the study results, decreasing 
adherence was associated with increasing treatment 
failure. The study also found that many patients 
overestimated their adherence levels. Two other studies 
determined that physicians did poorly in estimating 
patient adherence. A survey of nationally representative 
subjects showed that adherence was associated with 
how well the regimen fit with the subject's daily lifestyle, 
but that compliance was not correlated with the number 
of pills taken or the number of medications prescribed. 
Additionally, the survey showed poor adherence to be 
associated with drug or alcohol use, while another study 
indicated that untreated depression was associated with 
decreased patient adherence. 
Canada Approves AIDS Drug Sustiva 
Reuters (03/23/99) 
Canadian health authorities have approved the non-
nucleoside reverse transcriptase inhibitor Sustiva for use 
against HIV-1, reports manufacturer DuPont Co. Sustiva is 
the first once-daily anti-HIV medication to be approved by 
the Canadian Health Protection Branch. 
Lipid Abnormalities Associated With Protease 
Inhibitors 
Journal of the Assoc. of Nurses in AIDS Care (03/99) 
A team of researchers from Regions Hospital in St. 
Paul, Minn., reports that protease inhibitor therapy for HIV 
infection may result in high lipid levels in a large 
percentage of patients. The scientists, led by N. Holly 
Melroe, investigated lipid abnormalities in association 
with three different protease inhibitor regimens in 136 
HIV-patients. Eighty percent of the patients on 
norvir/saquinavir showed a significant increased in 
cholesterol, as did 51 percent of patients on indinavir and 
47 percent of patients on nelfinavir. An audit of patients 
found that 91 percent of 40 patients on 
ritonavir/saquinavir combination therapy had elevated 
and abnormal cholesterol after the initiation of therapy. 
Comparatively, 71 percent of patients on other protease 
inhibitors showed similar results, while only 35 percent of 
patients on non-protease inhibitor therapies and just 17 
percent of patients not receiving therapy had elevated 
cholesterol levels. The researchers note that extended use 
of protease inhibitors may be risky and possibly have a 
greater life-threatening potential than HIV infection itself 
for some patients. 
HIV Drug News 
Changing Trends in HIV-Related Morbidity Confirmed in 
New York City 
Reuters Health lnfonnation SeNices (03/29/99) 
Researchers report in the February issue of AIDS that 
there has been a decline in the number of HIV-related 
hospital admissions and opportunistic infections in New 
York City since the introduction of highly active 
antiretroviral therapy (HAARTI. Researchers analyzed the 
records of HIV-infected patients at the New York Hospital-
Comell Medical Center during two six-month intervals: one 
in 1995 - before HAART was available - and one in 1997. 
The researchers determined that there was a significant 
decrease in admissions, opportunistic infections, and death 
among the 1,500 HIV-positive outpatients they followed 
during the study. Median CD4 cell counts also increased 
among patients during the study. 
AIDS Fighters Pin Hopes on Immune Therapies 
St. Louis Post-Dispatch Online (03/26/99) 
Small-scale trials of anti-HIV drugs reported at the 11th 
annual National HIV/AIDS Update Conference in San 
Francisco show promise in the fight against AIDS. 
Immune-based therapies, such as interleukin-2, Remune, 
and GM-CSF. may help boost response to combination 
therapy. lnterleukin-2 treatment in combination with anti-
retroviral drugs helped some subjects produce a prolonged 
response, lasting almost two years in some patients. 
Remune appears to help patients respond against multiple 
HIV subtypes, while GM-CSF may aid in the clearance of 
HIV from the body. None of the treatments have been 
proven efficacious in large-scale trials, though, and 
frequent side effects are a problem. 
Initial HAART Discontinued at Rate of About 25 % Yearly 
Reuters Health lnfonnation SeNices (03/25/99) 
Dutch researchers report that each year about one-
quarter of patients who receive highly active antiretroviral 
therapy (HAARTI discontinue their initial regimen. A study 
published in the Journal of Acquired Immune Deficiency and 
Human Retrovirology showed that of 99 patients followed 
for 450 days, three patients withdrew from treatment and 
27 patients altered their HAART regimen. Additionally, more 
than 50 percent of patients with low CD4 + cell counts 
discontinued initial treatment within one year. The authors 
concluded that many patients discontinue initial HAART 
treatment because of insufficient response to treatment or 
due to side effects. 
The Effect of Combination Antiretroviral Therapy Soon 
After HIV Infection 
Journal of Infectious Diseases Online (03/99) 
Researchers from the Aaron Diamond Research Center 
in New York, and others, investigated whether HIV-1 can be 
cleared from infected individuals with the initiation of 
lamivudine. zidovudine, and ritonavir therapy within 90 
days of acute symptom onset. They treated 12 subjects and 
found that viral replication was suppressed in adherent 
subjects during the two-years of therapy. However, all 
subjects showed the persistence of proviral DNA in 
mononuclear cells. The authors also found a decrease in 
HIV-1 specific antibodies and cytotoxic T lymphocyte 
response in selected subjects. Vaccine strategies designed 
to enhance these functions may be prudent before the 
withdrawal of antiretroviral therapy, the researchers said. 
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HIV News 
AIDS Drastically Cuts Life Spans in So. African Nations 
Philadelphia Inquirer (03/19/99) 
The U.S. Census Bureau reports that people in five 
southern African nations have the shortest life spans in the 
world - under 40 years -- due to high AIDS mortality rates. 
Furthermore, Andrew Mutandwa, spokesman for the 
Southern African AIDS Information Dissemination Service, 
predicts that average life spans in Botswana, Zimbabwe, 
Swaziland, Malawi, and Zambia will continue to decrease. 
Prior to the AIDS epidemic, average life spans in the five 
nations measured above 65 years. The census bureau also 
reported that life spans in Ethiopia, Namibia, Rwanda, and 
Uganda have fallen to under 45 years. The 21 countries with 
the highest AIDS death rates in the world are in Africa, with 
over two-thirds of the global AIDS population located in 
Africa. Southern Africa has been most affected by AIDS, 
which some experts believe is due in part to its extensive 
highway system. 
Scientists Say HIV Originates From 
Long-Tailed Monkeys 
Kyodo News SeNice (03/27/99) 
Japanese scientists at Kyoto University report that HIV-1 
could have originated in long-tailed monkeys in Africa. Last 
January, U.S. researchers said they had found proof that 
HIV-1 originated in chimpanzees, but the Japanese 
researchers said they found viruses similar to HIV-1 in drills -
- which are similar to mandrills -- in central Africa. They 
assert that the viruses are HIV-1 prototypes. 
Miami's Black Clergy Prodded on AIDS 
Miami Herald (03/16/99) 
Speaking at a conference in Miami, Fla., the Rev. Jesse 
Jackson challenged the Miami-area African-American 
church community to increase its AIDS activism. Jackson 
criticized fellow ministers for their reluctance to confront 
the issue, urging ministers to get tested for HIV in a show of 
leadership. AIDS is the leading cause of death among 
African-Americans aged 25 to 44 and is the fourth leading 
cause of death among all African-Americans in Florida. 
Miami has the third highest AIDS rate among African-
Americans in major U.S. cities. There are an estimated 
30,000 HIV-infected people in the Miami-Dade County area, 
about 50 percent of whom are African American and one-
third of whom are Hispanic. 
Across the USA: Idaho 
USA Today (03/22/99) 
In Idaho, seven people in Idaho Falls and Pocatello have 
recently been diagnosed with HIV. State health officials said 
that the infected people probably contracted the virus from 
heterosexual sex with different partners. They called the 
outbreak a wake-up call to the region. 
HHS Announces $710 Million in Grants for HIV/AIDS 
U.S. Newswire (04/06/99) 
In an effort to increase access to HIV/ AIDS primary care 
and related services, the U.S. Dept of HHS awarded formula 
grants worth $710 million to the 50 states, the District of 
Columbia, and the U.S. territories. State AIDS Drug 
Assistance Programs will receive $461 million of the funds, 
to help infected individuals buy HIV medications. HHS 
Secretary Donna E. Shalala said, "These grants reaffirm the 
administration's commitment to provide vital HIV/ AIDS 
health care to communities most in need." 
HIV News 
AIDS Still an Epidemic; Cases on Rise 
MSNBC Online (03/16/99) 
Research conducted by Stella Theodoulou, chair of the 
political science department at California State University 
at Northridge, indicates that the AIDS rate is continuing to 
rise in some parts of the population in Los Angeles County. 
Using data from 1982 through 1997, Theodoulou found 
that rates are increasing substantially in certain 
populations, including African-Americans, Hispanics, and 
women. She said that media reaction to the disease 
creates the impression that the epidemic will soon be 
contained, which in tum misleads policy makers. 
Advertising The Facts About AIDS 
New York Times (03/17/99) 
The American Foundation for AIDS Research (Amfar) 
and the advertising agency Young and Rubicam will team 
up in an effort to fight public complacency on AIDS issues. 
Amfar is also trying to raise donation levels by $4 million to 
$22 million a year. Young and Rubicam, Cato Johnson, 
Landor Associates, Burson-Marsteller, and Kenneth Cole 
Productions will all contribute to the campaign. In all, 
television and radio networks will contribute over $2 
million in commercial time and ad space. Amfar and Young 
and Rubicam seek an additional $3 million in ad space and 
commercial time. 
HIV Treatment News 
Elective Caesarean-Section Versus Vaginal Delivery in 
Prevention of Vertical HIV-1 Transmission" 
lancet (03/27/99) 
The European Mode of Delivery Collaboration 
conducted randomized clinical trials to assess possible 
vertical HIV transmission risk-reduction associated with 
caesarean-section delivery. The researchers assigned 
eligible HIV-positive pregnant women for either elective 
caesarean delivery or for vaginal delivery. Of 370 infants 
born to the women, 170 infants were born to women 
assigned to the elective caesarean-section delivery 
group. Three of these children ( 1.8 percent) were found to 
be HIV-positive by age 18 months. Comparatively, 21 of 
the 200 children ( 10.5 percent) born to women designated 
for vaginal delivery were HIV-positive after 18 months. 
Seven of 203 infants (3.4 percent) who were actually 
delivered through caesarean section contracted HIV, 
while 15 of 167 (10.2 percent) of children delivered 
vaginally contracted the virus. 
The researchers conclude that "elective cesarean-
section delivery significantly lowers the risk of mother-to-
child transmission of HIV-1." They add that few 
postpartum complications and no serious side effects 
were observed among any of the women. 
Men's Health Project· Sanford, Yark County 
HIV Treatment News 
Quality of Life and Self-Care Management Strategies of 
PLWA's With Chronic Diarrhea 
Journal of the Association of Nurses in AIDS Care (03/99) 
Researchers from the University of California, San 
Francisco, surveyed 20 people living with AIDS (PLWA's) 
who reported chronic diarrhea and 20 PLWA's without 
chronic diarrhea to analyze quality of life issues associated 
with diarrhea in AIDS patients. Diarrhea often results from 
pathogens, such as cryptosporidium and isoporabelli, and 
medications, such as antibiotics and nucleoside reverse 
transcriptase inhibitors. The researchers, led by Suzanne 
Bakken Henry, found that PLWA's without chronic diarrhea 
reported significantly higher general health perceptions. 
They also reported increased fatigue, greater psychological 
distress, and greater gastrointestinal discomfort. 
The majority of patients with chronic diarrhea used 
dietary supplements, vitamins, and medications for self-
management of their digestive problems. However, only 40 
percent reported following a special diet and one-quarter 
said they used herbs to treat the diarrhea. Some common 
dietary restrictions included the avoidance of caffeine, 
sorbitol, alcohol, and insoluble fiber, with the limitation of fat 
and lactose intake. 
PLWA's with chronic diarrhea also reported significant 
pain (60 percent of respondents), weight loss greater than 
10 pounds ( 45 percent), decreased social activity ( 45 
percent) and decreased sexual activity (20 percent). The 
authors conclude that the quality of life limitations created 
by chronic diarrhea support the need for symptom 
management interventions. 
Factors Associated Wrth Refusal to Treat HIV-Infected 
Patients: The Results of a National Survey of Dentists in 
Canada 
American Journal of Public Health (04/99) 
Researchers from the University of Western Ontario 
conducted a survey of dentists in Canada to assess the 
percentage of care providers who refuse to treat HIV-
infected patients. Of 4, 107 respondents, 16 percent said 
they would refuse treatment to HIV-positive patients. 
Treatment refusal was most strongly associated with lack 
of belief in an ethical responsibility to treat infected 
patients, while staff fears, patient loss, cost of infection 
control, and safety concerns also played a role. 
Overall, 81 percent of dentists said they would treat HIV-
positive patients, with 86 percent reporting that they would 
treat injection drug users, and 87 percent replying that they 
would treat patients infected with hepatitis B virus. Ninety-
four percent of respondents would treat homosexual and 
bisexual patients, while 94 percent said they would treat 
people with sexually transmitted diseases, and 97 percent 
said they would treat recipients of blood and blood 
products. Almost one-third of respondents said they had 
knowingly treated an HIV-infected patient within the prior 
year. Current Canadian Dental Association guidelines state 
that dentists must not refuse patients solely on the grounds 
of HIV infection. 
Thursday Evenings. 7-9 p.m., Sanford, Maine. May 6-June 24, 1999 (transportation available) 
Are you a man who has gay sex, and may or may not call yourself ' gay'? Are you just 'coming out', but dont wantto be labeled? Are you 
perhaps married? Are you already out, but want to meet other men to relate around healthy sexuality, relationships, and other issues? 
You (especially TAP clients) are invited to a free, totally confidential, eight-week program for men who have sex with men, regardless of 
age, marital status, or HIV status. The group will be led by two professional health educators from The AIDS Project's Men's Wellness 
Program. All we ask is that you pre-register (confidentiality assured) and agree to come to all 8 sessions. The group meets at a downtown 
Sanford location, every Thursday evening in May and June from 7 to 9 p.m. First meeting: May 6th. 
To register, call Geny at (207) 774-6877 or 1-800-851-2437. ~ 
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PRO.JECT 
SUPPORT GROUPS 
FOR PEOPLE INFECTED 
AND AFFECTED BY HIV/AIDS 
MONDAYS 
Time: 5:00 p.m. to 6:30 p.m. 
Group: HIV and Substance Abuse 
Location: Portland, The Meeting Room, Suite 632. 
Contact Carolyn Curtis at TAP at 774-6877, or David 
Gordon at Portland Public Health at 874-8784. 
TUESDAYS 
Time: 10:30 a.m. to noon 
Group: HIV Infected/Affected Drop-In Support Group 
A meeting for people living with and affected by the virus. 
Location: Portland, TAP. The Meeting Room, Suite 632. 
Contact Susan Parr atTAP at 774-6877 for more info. 
THURSDAYS 
PRO.JECT 
CLIENT SERVICES 
MEDICAL ASSISTANT FUNDS 
An important reminder to clients: 
There are funds available to TAP clients with financial need 
for the following items: Routine Dental Care, Routine Eye 
Care and Eyeglasses, Vitamin Supplements, Non-
Prescription Skin Care Products, and Non-Medicaid 
Medication Co-pays. 
There is a dollar limit to how much a client can receive in any 
fiscal year. Contact your case manager for assistance. 
IMMEDIATE SEATING 
For free tickets to area events as they become available, 
sign up for "Immediate Seating." Call Daniel at TAP at 774-
6877 for more information. 
I.V. LEAGUE 
Meetings of the I.V. League support group are held on 
Time: 10:00 a.m. to 11 :30 a.m. Thursdays from 10:00 to 11 :30 a.m. at First Parish Church 
Group: HIV Infected/Affected Drop-in Group at 425 Congress St. in Portland. (Use the right side entrance 
A TAP-sponsored meeting for people and ring the bell) 
living with and affected by HIV/AIDS in southern Maine. For more information, call Steve Farrell at 874-8775. 
Location: Sanford, Unitarian Church, located at the comer of 
MainSt.(Rte. 109)andLebanonSt.(Rte. 202). THE MEETING ROOM 
ContactGettyPaysonatTAPat985-8199formoreinfo. This room is used by TAP in Portland for support groups, 
Time: 12 noon 
Group: Open Lunch for TAP Clients/Staff 
An informal luncheon gathering ofTAP staff and clients. 
Location: Portland, TAP. Conference Room. 
Contact Daniel Schnorbus at TAP at 77 4-6877 for info. 
Time: 5:30 p.m. to 7:00 p.m. 
Group: People Living with HIV/AIDS 
A drop-in support group for anyone with HIV/ AIDS. 
Location: Portland, TAP. The Meeting Room, Suite 632. 
Contact Susan Parr at TAP at 774-6877 for more info. 
>>>>New Group<<<< 
Whan: Day and Time to be announced 
Group: Expressive Therapy 
counseling and testing, and some client/case manager 
meetings. Located in Suite 632, it provides more privacy for 
people served by TAP. 
Enter from the High Street side of the building. 
FOR YOUR INFORMATION 
TAP ON-LINE 
Visit our new website at: www.aidsprojact.org 
To e-mail The AIDS Project, 
send your message along to: 
tap@aidsprojact.org (Portland) 
or tap2@mail.javanat.com (Kennebunk) 
HIV WEBSITES Explore your creativity through art, music, movement. 
Location: Portland, The Meeting Room, Suite 632. 
Contact Susan Parr at TAP at 774..{;877 for more info. 
Check out these websites: 
www.hivpositiva.com 
________________ www.thabody.com 
www.projinf.org 
for info on HIV and AIDS. York County Clients 
York County Clients of TAP can use the computer at its Ai DS HOTLINE$ 
Kennebunk office to access the internet. Call Getty Questions about HIV/ AIDS? 
Payson at 985-8199 to set up a time to use the computer. Call toll-free 
Also, clients can now e-mail TAP's Kennebunk office at: 
www.tap2@mail.javanat.com 
National AIDS Hotline: 
1-800-342-2437 
Maine AIDSline: 
---------------- 1-800-851-2437 
WELLNESS AND YOU PROGRAM 
A stress reduction and physical activity program 
designed for people living with HIV/ AIDS. In this program 
individuals can participate in a variety of supervised 
physical activity, education, and specialized stress 
management segments. Contact Daniel at TAP at 774-
6877 for more information. 
For more infonnation about programs 
The AIDS Project, call Susan Parr, TAP's 
Support Group Manager, at 774-6877. 
Maine Teen Hotline: 
1-800-851-2437 
(on Wednesdays from 6-9pm) 
IN THE AFFIRMATIVE 
In The Affirmative is a monthly 
newsletter published by The AIDS 
Project for people living with and 
affected by HIV/AIDS. Letters, articles, 
or other submissions should be sent to: 
In The Affirmative, c/o The AIDS 
Project, P.O. Box 5305, Portland, ME 
04101, or call (207) 774-6877. 
Submissions can be printed anony-
mously as long as the person submit-
ting the material includes his or her 
name and phone number for verifica-
tion. 
News, information, and features are 
as up-to-date as possible prior to 
publication. Any medical information 
included in this newsletter is submitted 
for the reader's information only, to be 
used as the reader so chooses. 
Sources for some of the information 
in this newsletter include: 
CDC HIV/STD/TB Prevention 
News Update 
Contributors include: 
Denise Ferer 
Demetra Giatas 
Sandy Putnam 
Daniel Schnorbus 
Gerry Scoppettuolo 
People Art © David Cedrone 
Kerry S. Tardiff, Distribution 
Mike Martin, Editor 
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